<DOC>
	<DOCNO>NCT02295332</DOCNO>
	<brief_summary>This single center , randomize , double-blind , placebo-controlled , single ascend dose study evaluate safety , tolerability , pharmacokinetics pharmacodynamic effect single dos RG7625 healthy male female volunteer . The study employ interleave cohort ( 'leapfrog ' ) design dose alternate two cohort individual within cohort receive study drug dose four occasion - effect give four treatment , four period , four-way crossover individual . The minimum duration participant approximately 8 week .</brief_summary>
	<brief_title>A Study RG7625 Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy male female participant , 18 60 year age , inclusive A body mass index 18 30 kg/m2 inclusive Able participate willing give write informed consent comply study restriction Any clinically relevant abnormality , concomitant disease ongoing medical condition , abnormal laboratory test result history clinically significant disorder Any major illness within one month precede screen visit , febrile illness within two week precede screen visit Any significant allergic reaction drug Immunocompromised reduce immune function and/or immunization within 30 day first study drug administration plan vaccination study Women pregnant lactate childbearing potential Clinically significant abnormal ECG risk factor QT prolongation Use prescribe counter medication Inability unwillingness comply study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>